[go: up one dir, main page]

MX2020011020A - Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. - Google Patents

Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2.

Info

Publication number
MX2020011020A
MX2020011020A MX2020011020A MX2020011020A MX2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A MX 2020011020 A MX2020011020 A MX 2020011020A
Authority
MX
Mexico
Prior art keywords
isoforms
pharmaceutically effective
selectively inhibit
effective compounds
inhibit myosin
Prior art date
Application number
MX2020011020A
Other languages
English (en)
Inventor
Sándor Bátori
András Szabó
József Répási
András Málnási-Csizmadia
Máté Gyimesi
Péter Hári
Suthar Sharad Kumar
Mihály Kovács
Ádám István Horváth
Máté Pénzes
István Lorincz
Zoltán Szonyegi
Zoltán Simon
László Végner
Vajk Horváth
Original Assignee
Printnet Kereskedelmi Es Szolgaltato Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Printnet Kereskedelmi Es Szolgaltato Kft filed Critical Printnet Kereskedelmi Es Szolgaltato Kft
Publication of MX2020011020A publication Critical patent/MX2020011020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) o (II) (ver Fórmulas) sales, solvatos, tautómeros, estereoisómeros farmacéuticamente aceptables de los mismos, incluidos enantiómeros, diastereómeros, mezclas racémicas, mezclas de enantiómeros o combinaciones de los mismos, y usos farmacéuticos de los compuestos.
MX2020011020A 2018-04-18 2019-04-18 Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. MX2020011020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1800129A HU231285B1 (hu) 2018-04-18 2018-04-18 A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
PCT/HU2019/050017 WO2019202346A2 (en) 2018-04-18 2019-04-18 Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms

Publications (1)

Publication Number Publication Date
MX2020011020A true MX2020011020A (es) 2021-01-08

Family

ID=89992670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011020A MX2020011020A (es) 2018-04-18 2019-04-18 Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2.

Country Status (21)

Country Link
US (3) US11746112B2 (es)
EP (2) EP3781263B1 (es)
JP (2) JP7463344B2 (es)
KR (1) KR20210010465A (es)
CN (2) CN112334191B (es)
AU (1) AU2019256801C1 (es)
BR (1) BR112020021347A2 (es)
CA (1) CA3097479A1 (es)
DK (1) DK3781263T3 (es)
ES (1) ES2963548T3 (es)
FI (1) FI3781263T3 (es)
HU (2) HU231285B1 (es)
IL (1) IL278105B2 (es)
MA (1) MA52298A (es)
MX (1) MX2020011020A (es)
PH (1) PH12020551734A1 (es)
PL (1) PL3781263T3 (es)
PT (1) PT3781263T (es)
SG (1) SG11202010177UA (es)
SI (1) SI3781263T1 (es)
WO (1) WO2019202346A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN112584832A (zh) 2018-06-14 2021-03-30 斯克里普斯研究学院 用于物质使用复发的非肌肉肌球蛋白ii抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR861530B (en) 1985-06-13 1986-12-31 Schering Corp Preparation process for polycyclic quinoline of naphthyridine and pyrazinopyridine
CN101243082A (zh) * 2005-06-17 2008-08-13 詹森药业有限公司 治疗cns障碍的六氢－吡咯并－异喹啉化合物
JP2011510933A (ja) 2008-01-31 2011-04-07 モナシュ ユニバーシティ 血栓塞栓性障害を治療する方法
EP2323659A4 (en) * 2008-08-05 2012-03-14 Abbott Lab COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES
US8609417B2 (en) 2009-04-13 2013-12-17 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2011137485A1 (en) 2010-05-05 2011-11-10 Sydney Ivf Limited Media and methods for cell culture
HUP1000366A2 (en) * 2010-07-13 2012-03-28 Mta Enzimologiai Intezet Novel proteins, their production process and use tereof
EP2492687A1 (en) 2011-02-23 2012-08-29 Institut Gustave Roussy -Igr- MYH10 as a new diagnostic marker of pathologies resulting from RUNX1 inactivation
US9994564B2 (en) * 2011-05-18 2018-06-12 Michael E. DiSanto Myosin II ATPase inhibitor compounds
WO2012158942A2 (en) 2011-05-18 2012-11-22 The Cooper Health System Drug treatment of overactive bladder
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
EP2777703B1 (en) * 2013-03-15 2016-09-14 Lonza Cologne GmbH Compositions and methods for enhancing the therapeutic potential of stem cells
MA39203A1 (fr) * 2014-02-18 2017-10-31 Francais Du Sang Ets Typage de hla à haute résolution
EP3277799B1 (en) 2015-04-03 2020-09-23 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
WO2017129782A1 (en) * 2016-01-29 2017-08-03 Paris Sciences Et Lettres - Quartier Latin Water-soluble myosin 2 inhibitors for the treatment of neurological, neuropathic or psychiatric diseases
CN112004533A (zh) 2018-02-20 2020-11-27 艾知怀斯治疗学公司 治疗运动障碍的方法和组合物
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN112584832A (zh) 2018-06-14 2021-03-30 斯克里普斯研究学院 用于物质使用复发的非肌肉肌球蛋白ii抑制剂
AU2019376065B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof

Also Published As

Publication number Publication date
DK3781263T3 (da) 2023-10-02
IL278105B2 (en) 2024-05-01
WO2019202346A2 (en) 2019-10-24
HU231285B1 (hu) 2022-08-28
AU2019256801A1 (en) 2020-12-17
EP4276102A2 (en) 2023-11-15
IL278105B1 (en) 2024-01-01
US20210087201A1 (en) 2021-03-25
WO2019202346A3 (en) 2019-12-19
CN112334191A (zh) 2021-02-05
EP3781263B1 (en) 2023-07-12
US11746112B2 (en) 2023-09-05
PT3781263T (pt) 2023-10-13
US20240270752A1 (en) 2024-08-15
US20230339959A1 (en) 2023-10-26
JP7463344B2 (ja) 2024-04-08
HUE063424T2 (hu) 2024-01-28
PL3781263T3 (pl) 2024-01-22
CN112334191B (zh) 2024-12-10
AU2019256801B2 (en) 2024-09-26
MA52298A (fr) 2021-02-24
US12421243B2 (en) 2025-09-23
JP2021522322A (ja) 2021-08-30
BR112020021347A2 (pt) 2021-01-19
SI3781263T1 (sl) 2024-01-31
AU2019256801C1 (en) 2025-02-13
PH12020551734A1 (en) 2021-06-07
US11845758B2 (en) 2023-12-19
FI3781263T3 (fi) 2023-09-15
KR20210010465A (ko) 2021-01-27
IL278105A (es) 2020-12-31
EP3781263A2 (en) 2021-02-24
CN117924285A (zh) 2024-04-26
CA3097479A1 (en) 2019-10-24
SG11202010177UA (en) 2020-11-27
ES2963548T3 (es) 2024-03-27
EP4276102A3 (en) 2023-12-06
JP2024075759A (ja) 2024-06-04
HUP1800129A1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
EA202091506A1 (ru) Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
CL2023003308A1 (es) Compuestos heterocíclicos sustituidos
PH12016501440A1 (en) Novel heterocyclic compounds
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA202092383A1 (ru) Ингибиторы комплемента на основе замещенного бензофурана, бензопиррола, бензотиофена и их структурных производных
MX390625B (es) Inhibidores selectivos de jak1.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
MX420195B (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
EA201991123A1 (ru) ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MX2019005234A (es) Amidas y aminas de azol como inhibidores de integrina alfa v.
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
EA202191519A1 (ru) Модуляторы trex1
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1